Imiquimod NDC 68682-272

NDC codes

FDA NDC Directory

Product NDC (as listed)68682-272Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68682-0272Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68682-272-75	68682027275	1 BOTTLE, PUMP in 1 CARTON (68682-272-75) / 7.5 g in 1 BOTTLE, PUMPMarketed from Jun 27, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Imiquimod
Generic name (nonproprietary): imiquimod
Active ingredients: Imiquimod — 37.5 mg/g
Dosage form: Cream
Route: Topical
Labeler: Oceanside Pharmacueticals
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022483
Marketing start: Jun 27, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Increased Cytokine Activity (Physiologic effect)Increased Cytokine Production (Physiologic effect)Interferon Inducers (Mechanism)
Identifiers: Product ID 68682-272_36b25854-8ed2-8f45-e063-6294a90a8b46SPL ID 36b25854-8ed2-8f45-e063-6294a90a8b46SPL set ID d86eeb0e-70e0-4c72-aaa3-37daa1d8611eRxCUI 967017UNII P1QW714R7M

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468682027275 followed by a unit qualifier and the quantity

Package 68682-0272-75. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 3, 2025.

Indications (excerpt from the label)

Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible, or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. ( 1.1 ) Imiquimod Cream, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age or older. ( 1.2 ) 1.1 Actinic Keratosis Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. 1.2 External Genital Warts Imiquimod Cream, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022483

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022483
Product	Strength	Form · route	Labeler	Product NDC
Imiquimod	Imiquimod 37.5 mg/g	CreamTopical	Teva Pharmaceuticals USA, Inc.	0093-3133
Zyclaraimiquimod	Imiquimod 37.5 mg/g	CreamTopical	Bausch Health US, LLC	99207-270
Zyclaraimiquimod	Imiquimod 37.5 mg/g	CreamTopical	Bausch Health US, LLC	99207-271
Zyclaraimiquimod	Imiquimod 2.5 mg/g	CreamTopical	Bausch Health US, LLC	99207-276